Negotiators dropped patent and copyright demands but failed to garner agreement.
The EU and India are taking steps to end a trade row sparked by an EU ban of 700 Indian pharmaceutical products after New Delhi cancelled talks on a free trade accord earlier this month.
Time is running out for a congressional vote on a completed TPP deal during President Obama’s term of office.
Data exclusivity is a kind of super-patent that is an incredibly powerful form of monopoly.
A big supplier of cheap lifesaving drugs to developing nations, India admirably balances public health needs with private profits and innovation. But it is under pressure to change this model.
Objecting to the ban of around 700 pharma products by the European Union, India said that it has called off a scheduled meeting of chief negotiators of the two sides on the proposed free trade agreement
Knowledge Ecology International released text from three sections of the 95-page secret negotiating text on the Intellectual Property Chapter being used in the Trans-Pacific Partnership Agreement trade negotiations
Prime Minister John Key has conceded New Zealand will have to pay more for some medicines under the Trans-Pacific Partnership but he says it is in the country’s best interests
Ten years ago today, in the dead of night, Congress passed the US-Central America Free Trade Agreement by two votes. Lessons learned from the actual effects of CAFTA on access to affordable life-saving prescription drugs provide a vivid illustration of the impact of TPP-like rules on people and their health.
The Trans-Pacific Partnership Agreement reportedly contains provisions that would lead to higher drug prices, not just in the TPPA but in future trade agreements as well, UNAIDS warns.
As the negotiations for the Trans-Pacific Partnership Agreement (TPPA) enter what could be its last round, we as people living with HIV/Aids (PLHIV), urge the Malaysian government not to trade away our lives.
Oone issue that has received comparatively little attention is how the Trans-Pacific Partnership is likely to impact the developing countries slated to join.
Experts say the government should carefully consider before signing free-trade agreements (FTA) - as people could be hurt by deals that prolong drug patents and restrict information about medicine.
New Zealand needs to be ready to walk away from the Trans Pacific Partnership, says The Domion Post, worried about the impact of its drug patenting rules and investor-state dispute settlement mechanism.
A recent draft of the Trans-Pacific Partnership free-trade deal would give US pharmaceutical firms unprecedented protections against competition from cheaper generic drugs, possibly transcending the patent protections in US law.
The Australian government misrepresents the claims of critics and fails to address substantial criticisms of the Trans Pacific Partnership, says civil society network AFTINET.
Recently leaked documents show that India’s policies on software and pharmaceutical patents are firmly on the RCEP agenda.
NZ is heading towards a two-tier health system, and it could get a whole lot worse, writes George Laking.
As the eighth round of negotiations on the Regional Comprehensive Economic Partnership (RCEP) trade agreement take place in Kyoto, Japan this week, farmer’s groups, trade unions, civil society and patient groups are urging the Indian Government to halt the negotiations, make the negotiating texts public and hold consultations with all the relevant stakeholders, in light of the potential negative impact this agreement could have on access to medicines, livelihood of farmers, quality public services and overall social and economic development of the country.
On Wednesday 10 June 2015, WikiLeaks published the Healthcare Annex to the secret draft "Transparency" Chapter of the Trans-Pacific Partnership Agreement (TPP), along with each country’s negotiating position.